Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Registry to Document Treatment Effectiveness, Safety, Including Prospective Long-term Outcomes in Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay)

NCT07185919 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT07185919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07185919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Registry to Document Treatment Effectiveness, Safety, Including Prospective Long-term Outcomes in Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay)
Lead sponsor
Ipsen
Phase
Observational
Overall status
Recruiting
Start date
October 30, 2025
Completion date
September 30, 2032
Enrollment
10 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

progressive familial intrahepatic cholestasis